Edition:
United Kingdom

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

2.10USD
18 May 2018
Change (% chg)

$0.10 (+5.00%)
Prev Close
$2.00
Open
$2.10
Day's High
$2.10
Day's Low
$2.10
Volume
4,864
Avg. Vol
8,202
52-wk High
$2.85
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Proteon Says Has Sufficient Capital For Operations Into Q4 Of 2019
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Proteon Therapeutics Inc ::PROTEON THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.PROTEON THERAPEUTICS INC - HAS SUFFICIENT CAPITAL TO FUND COMPANY'S OPERATIONS INTO Q4 OF 2019.PROTEON THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE INVESTMENTS TOTALED $42.1 MILLION AS OF DECEMBER 31, 2017.  Full Article

Proteon Therapeutics Q3 ‍loss per share $1.08​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces third quarter 2017 financial results.Remain on-track to complete enrollment in Q1 of 2018 in patency-2, co's second phase 3 clinical trial of vonapanitase​.Qtrly ‍loss per share $1.08​.Expects its cash, cash equivalents, available-for-sale investments will be sufficient to fund its operations into Q4 of 2019,.Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Proteon Therapeutics Q2 loss $0.33 per share
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces second quarter 2017 financial results.Proteon Therapeutics Inc - qtrly net loss per share attributable to common stockholders basic and diluted $0.33.Proteon Therapeutics Inc - expects cash, cash equivalents and available-for-sale investments will be sufficient to fund its operations into Q4 of 2019.Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.  Full Article

Proteon Therapeutics files for shelf offering of up to 22.1 million shares
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics Inc files for shelf offering of up to 22.1 million shares of common stock by selling stockholders‍​ - sec filing.  Full Article

Deerfield Management reports 6.97 pct stake in Proteon Therapeutics - SEC filing
Thursday, 29 Jun 2017 

June 29 (Reuters) - Deerfield Management Company L.P.::Deerfield Management Company L.P. reports 6.97 percent stake in Proteon Therapeutics Inc as of June 22 - SEC filing.Anticipate Jonathan Leff, partner at Deerfield Management, to be named to board of directors of Proteon Therapeutics Inc.  Full Article

Proteon Therapeutics announces $22.0 mln private placement
Thursday, 22 Jun 2017 

June 22 (Reuters) - Proteon Therapeutics Inc ::Proteon Therapeutics announces $22.0 million private placement.Intends to use proceeds from transaction to complete ongoing patency-2 trial and fund continued market access activities.Private placement of 22,000 shares of company's series a convertible preferred stock for gross proceeds of $22.0 million.Holders of preferred stock will be entitled to elect one director to company's board of directors.Financing also extends company's cash runway from Q3 of 2018 into Q4 of 2019.  Full Article

Proteon Therapeutics qtrly net loss per share attributable to common stockholders $0.39
Wednesday, 10 May 2017 

May 10 (Reuters) - Proteon Therapeutics Inc : :Proteon Therapeutics announces first quarter 2017 financial results.Qtrly net loss per share attributable to common stockholders $0.39.Proteon Therapeutics - expects its cash, cash equivalents and available-for-sale investments will be sufficient to fund its operations into Q3 of 2018..  Full Article

Proteon says receives FDA breakthrough therapy designation for vonapanitase
Wednesday, 10 May 2017 

May 10 (Reuters) - Proteon Therapeutics Inc :Proteon therapeutics receives fda breakthrough therapy designation for vonapanitase.Proteon therapeutics inc- enrollment in patency-2 trial is expected to complete in q1 of 2018.Proteon therapeutics inc- proteon expects to report top-line data in q1 of 2019.Proteon therapeutics inc- proteon also expects to submit a bla to fda in 2019..Proteon therapeutics inc - proteon also expects to submit a bla to fda in 2019.  Full Article

Proteon Therapeutics announces increase to enrollment of ongoing phase 3 Patency-2 clinical trial
Tuesday, 2 May 2017 

May 2 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces increase to enrollment of ongoing phase 3 Patency-2 clinical trial.Proteon Therapeutics Inc - Will increase planned enrollment of its ongoing phase 3 Patency-2 trial to 600 patients.Proteon Therapeutics Inc- Increase in sample size does not alter study endpoints, which use same definitions as in Patency-1 trial.Proteon - Increased sample size follows review of statistical plan, which revealed calculation error that overstated trial's power for secondary patency.Proteon Therapeutics Inc says still expects to submit a biologics license application (BLA) to U.S. Food and Drug Administration (FDA) in 2019..Expects to complete enrollment in Q1 of 2018 for phase 3 Patency-2 trial and to report top-line data in Q1 of 2019.  Full Article

Proteon Therapeutics FY loss per share $1.72
Thursday, 16 Mar 2017 

Proteon Therapeutics Inc : Proteon Therapeutics announces full-year 2016 financial results and changes to the ongoing phase 3 patency-2 clinical trial . Proteon Therapeutics -expects its cash, cash equivalents and available-for-sale investments will be sufficient to fund its operations into Q3 of 2018 . Proteon Therapeutics Inc - expects to report top-line data in Q4 of 2018 for patency-2 trial . Proteon Therapeutics Inc - if patency-2 trial is successful, Proteon expects to submit a bla in 2019 .Proteon Therapeutics -FY loss per share $1.72.  Full Article